Video Reports

Hussein A. Tawbi, MD, PhD: Patients with stage III melanoma are defined as patients who have nodal involvement from their disease.

Hussein A. Tawbi, MD, PhD: In terms of the role of the BRAF mutation in melanoma, up to half the patients with melanoma have a BRAF mutation in their tumor.

Hussein A. Tawbi, MD, PhD: COMBI-AD was a large, randomized, global phase III trial that took patients with nodal involvement, so stage III patients—it was patients with stage IIIa, IIIb, and IIIc in the AJCC [American Joint Committee on Cancer Cancer Staging Manual] 7th edition—and randomized them to dabrafenib and trametinib as active therapy versus placebo.

Long-term data from the COLUMBUS trial showed that encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival (OS) and progression-free survival (PFS) compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.